Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

Rutgeerts, Paul; Vermeire, Severine; Van Assche, Gert
April 2007
Gut;Apr2007, Vol. 56 Issue 4, p453
Academic Journal
The main goal of treatment for Crohn's disease and ulcerative colitis has always been the induction and maintenance of symptomatic improvement or at best remission. It has been shown by many studies that the long-term outcome of these diseases is not influenced by standard treatments and that the need for surgery is not decreasing in this population over the years. There is recent evidence that with immunosuppression and treatment with infliximab long-term healing of the bowel can be achieved and that this affects the outcome of both Crohn's disease and ulcerative colitis. We propose that future studies should focus on healing and disease course as primary outcome measures.


Related Articles

  • The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? D'Haens, Geert R.; Panaccione, Remo; Higgins, Peter D. R.; Vermeire, Severine; Gassull, Miquel; Chowers, Yehuda; Hanauer, Stephen B.; Herfarth, Hans; Hommes, Daan W.; Kamm, Michael; Löfberg, Robert; Quary, A.; Sands, Bruce; Sood, A.; Watermayer, G.; Lashner, Bret; Lémann, Marc; Plevy, Scott; Reinisch, Walter; Schreiber, Stefan // American Journal of Gastroenterology;Feb2011, Vol. 106 Issue 2, p199 

    The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability,...

  • Use of biological therapy during pregnancy in the treatment of IBD. Thomas, Rosemarie // Gastrointestinal Nursing;Apr2009, Vol. 7 Issue 3, pS4 

    Ulcerative colitis and Crohn's disease often occur in the younger population, which means they are likely to affect women of child-bearing age. Infliximab and adalimumab, both biological therapies, are being increasingly used to treat moderate-to-severe inflammatory bowel disease (IBD) when...

  • MY THOUGHTS ON USING CYCLOSPORINE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE. Korelitz, Burton I. // American Journal of Gastroenterology;Dec1995, Vol. 90 Issue 12, p2085 

    Deals with the use of cyclosporine in the treatment of inflammatory bowel disease (IBD). Rationale in using cyclosporine in IBD and Crohn's disease; Overview of studies on the use cyclosporine in the treatment of IBD and Crohn's disease; Cases of using cyclosporin in patients with pneumonia;...

  • Therapierefraktäre chronisch entzündliche Darmerkrankungen: Eine chirurgische Herausforderung. Buhr, H.J.; Kroesen, A.J. // Der Chirurg;Nov2013, Vol. 84 Issue 11, p945 

    Surgery for inflammatory bowel disease under immunosuppressant drugs is a widely discussed topic. Because therapeutic concepts have significantly changed, almost no patient is currently without an immunosuppressant or biologic agent prior to surgery. However, the data whether biological agents...

  • The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease. Rutgeerts, P. // Mediators of Inflammation;Jun98, Vol. 7 Issue 3, p137 

    GLUCOCORTICOSTEROIDS are the mainstay of treatment of active Crohn's disease and ulcerative colitis. These drugs however carry important cosmetic short-term side effects and when used long-term they induce severe irreversible complications. Topically acting glucocorticosteroids, especially...

  • Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review. Oussalah, Abderrahim; Danese, Silvio; Peyrin-Biroulet, Laurent // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p156 

    The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC), refractory to conventional medications (corticosteroids, immunomodulators). This review summarizes current data on...

  • Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Gilroy, Leah; Allen, Patrick B. // Clinical & Experimental Gastroenterology;2014, Vol. 7, p163 

    Inflammatory bowel disease (IBD) is an important cause of morbidity and mortality for millions of patients worldwide. Current treatment options include corticosteroids, 5-aminosalicylates, immunosuppressants, and TNFa antagonists. However, these are frequently ineffective in achieving sustained...

  • Is infliximab good value for money in IBD?  // PharmacoEconomics & Outcomes News;7/1/2013, Issue 682, p7 

    The article discusses research on infliximab as maintenance treatment (MT) for inflammatory bowel disease. It references the studies "Cost-Effectiveness (CE) of Infliximab Scheduled MT for the Management of Patients With Moderate-to-Severe Ulcerative Colitis," by A. A. Tahami Monfared, et al,...

  • Use of azathioprine in IBD: modern aspects of an old drug. Louis, Edouard; Irving, Peter; Beaugerie, Laurent // Gut;Nov2014, Vol. 63 Issue 11, p1695 

    The article focuses on the use of azathioprine in the treatment of inflammatory bowel disease (IBD). Topics discussed include efficacy of azathioprine in treating Crohn's disease (CD), low cost and higher quality and effectiveness of thiopurines in the remission of CD patients, and thioguanine...


Read the Article


Sign out of this library

Other Topics